Korean pharmaceutical and biotech companies are set to establish a foothold on the global stage at the world’s largest biotech investment platform, the J.P. Morgan Healthcare Conference 2025.

The event will take place from Jan. 13 to 16 in San Francisco, California, featuring over 550 companies and more than 8,000 investors and industry experts.

Among the Korean firms officially invited to the conference are Samsung Biologics, Celltrion, Lotte Biologics, Hugel, Bridge Biotherapeutics, Onconic Therapeutics, and D&D Pharmatech. Each company aims to present their strategic vision and innovations to attract global partners and investors.

Samsung Biologics, participating for the ninth consecutive year, will have CEO John Rim deliver a main track presentation on Jan. 14. The company plans to showcase its advanced production facilities and next-generation antibody-drug conjugate (ADC) portfolio.

In response to increasing global demand for biopharmaceuticals, Samsung Biologics is constructing a fifth plant with a capacity of 180,000 liters, set to begin operations in April. The company has also launched four new custom development services last year and is on track to complete an ADC-specific production facility soon.

Celltrion will unveil its drug pipeline and biosimilar development progress, highlighting three ADC drugs and three multispecific antibody drugs under development, aiming for commercial launch by 2029, on Jan. 14. However, the company has yet to unveil who will make the presentation.

The company’s presentation follows its recently establishment of Celltrion BioSolutions, a dedicated contract development and manufacturing organization (CDMO), which plans to break ground on its first plant next year.

Celltrion also aims to establish specialized research centers in the U.S., Europe, and India, integrating technology-driven solutions into its CDMO offerings.

Lotte Biologics, under newly appointed CEO James Park, will reveal its vision for CDMO services and explore partnerships during the event on Jan. 16.

Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, will focus on strategic meetings with global pharmaceutical companies and investors to advance its global expansion of Nesuparib, a synthetic lethality-based anticancer drug candidate.

The company has validated the drug’s potential through multiple technology transfer agreements in China, India, and South America.

Bridge Biotherapeutics has been selected as a presenting company and will negotiate licensing deals for BBT-877 with leading global pharmaceutical firms. CEO Lee Jung-kue will present on Jan. 16, highlighting the company’s R&D initiatives and growth strategy to investors and industry stakeholders.

D&D Pharmatech will hold meetings with multinational pharmaceutical companies to discuss its main pipeline and platform technologies. The company is advancing clinical trials for DD02S, an oral GLP-1-based obesity treatment, and plans to demonstrate the potential of its ORALINK platform for peptide drugs. The company expects to validate ORALINK’s efficacy in humans in the first half of next year and has garnered significant interest from potential partners.

Other companies are also using the conference as a platform to enhance global outreach.

DXVX will introduce its room-temperature-stable mRNA platform and oral GLP-1 obesity drug to potential partners.

The company’s partnership with Pohang University of Science and Technology has yielded patents that address the challenges of ultra-cold storage for mRNA. DXVX also aims to complete preclinical trials for its oral obesity treatment next year and enter clinical stages by early 2026.

STCube will pursue licensing opportunities for its immunotherapy candidate Nelmastobart, targeting BTN1A1, a biomarker involved in regulating immune responses to cancer. The company stressed that it has scheduled meetings with multinational pharmaceutical firms to advance discussions.